Two Macquarie Private Wealth advisers have won their appeal of an order by the Australian Securities and Investments Commission that banned them for 10 years for falsifying emails and misclassifying client advice.
AFT not ready to take its medicine for ‘misleading’ Maxigesic ads
Clive Palmer hit with copyright suit by Universal Music over Twisted Sister song
WorkPac hit with class action by casual workers
Sanofi slams judge’s harm assessment in denying injector pen injunction
ASIC targets AMP execs in fees for no service probe, court told
Acciona mulls settlement with NSW Government in light rail dispute
AMP contractor pleads guilty to stealing customer data
Wyeth defends validity of patents in trial over best-selling Prevnar 13 vaccine
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.